Identification of potential corticosteroid binding sites on the SARS CoV-2 main protease Mpro — in silico docking study
Abstract
Background: Currently, an increase in the number of new cases of Covid-19 caused by the severe acute respiratory syndrome virus (SARS-CoV-2) is recorded in Ukraine and the world. SARS-CoV-2 provokes exacerbation of chronic diseases and activates inflammatory and allergic reactions. A severe course of Covid-19 increases the duration of hospitalization and the mortality rate among the population. Pathogenetic therapy is carried out with systemic corticosteroids, which suppress the cytokine storm by mitigating the SARS-CoV-2-induced systemic inflammatory response and inhibit SARS-CoV-2 main protease Mpro, a key component of viral replication.
Objectives: The aim of this study is to identify the potential corticosteroid binding sites on SARS CoV-2 main protease Mpro based on the analysis of the energetic and topological characteristics of the complexes as well as to investigate the inhibitory activity of selected corticosteroids against Mpro.
Material and Methods: The crystal structure of Mpro (ID: 6LU7 from Protein Data Bank) (www.rcsb.org) was chosen as a docking target. Molecular docking methods (AutoDock Tools 1.5.7, AutoDock Vina 1.1.2) were used to gain insight into the binding affinity Mpro with systemic corticosteroids such as dexamethasone (DEX), prednisone (PRED), prednisolone (PNL), methylprednisolone (Medrol), triamcinolone (TAC), and hydrocortisone (HCT). Visualization of docking results was done in PyMol 2.5. The protein-ligand interaction profiler (PLIP) and the LigPlot+ web tool were used to identify non-covalent interactions between Mpro and ligands (https://plip-tool.biotec.tu-dresden.de).
Results: In silico docking study demonstrated that all selected corticosteroids bound with amino acid residues of II and III domains of Mpro with binding energy in the range -7.8…-6.6 kcal/mol. The high binding affinity is found for dexamethasone-Mpro (-7.8 kcal/mol); for prednisone, prednisolone, methylprednisolone, triamcinolone, and hydrocortisone the binding energies were -7.4, -7.0, -7.5, -7.6 and -6.6 kcal/mol, respectively. It was shown that hydrogen bonds and hydrophobic interactions were involved in the formation of ligand-protein complexes mainly through residues such as Arg131, Lys137, Thr199, Asp289, Leu272, Leu286, Leu287, Tyr239, and Gly275, which formed the catalytic and distal sites for ligand binding. The inhibition constant of corticosteroids has ranged from 1.90 × 10-6 to 14.4 × 10-6 M.
Conclusion: Our results showed that the favorable binding sites for dexamethasone, prednisone, methylprednisolone, and triamcinolone are located in the catalytic site of domain II and the distal site of domain III of SARS-CoV-2 main protease Mpro with high binding affinities confirming the stability of the complexes. The low inhibition constants values for dexamethasone, prednisone, methylprednisolone, and triamcinolone further confirm the effectiveness of the selected corticosteroids as inhibitors of Mpro activity. Based on the binding energy as well as inhibition constants values dexamethasone, prednisone, methylprednisolone, and triamcinolone were identified as potential inhibitors for Mpro.
Downloads
References
Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Rev Med Virol. 2022;32(5):e2381. https://doi.org/10.1002/rmv.2381
Wu F, Zhao S, Yu B, Chen Y, Wang W, Song Z, et al. A new coronavirus associated with human respiratory disease in China [published correction appears in Nature. 2020 Apr;580(7803):E7]. Nature. 2020;579(7798):265–9. https://doi.org/10.1038/s41586-020-2008-3
Kangarshahi ZT, Lak S, Ghadam M, Motamed N, Sardari S, Rahimi S. The proteins of SARS- CoV-2 and their functions. Mil. Med. Sci. Lett. 2021;90(4):172–90. http://doi.org/10.31482/mmsl.2021.018
Grellet E, L'Hôte I, Goulet A, Imbert I. Replication of the coronavirus genome: A paradox among positive-strand RNA viruses. J Biol Chem. 2022;298(5):101923. https://doi.org/10.1016/j.jbc.2022.101923
Bhatt PR, Scaiola A, Loughran G, Leibundgut M, Kratzel A, Meurs R, et al. Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genome. Science. 2021;372(6548):1306–13. https://doi.org/10.1126/science.abf3546
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of MPro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289–93. https://doi.org/10.1038/s41586-020-2223-y
Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved -ketoamide inhibitors. Science. 2020;368(6489): 409–12. https://doi.org/10.1126/science.abb3405
She Z, Yao Y, Wang C, Li Y, Xiong X, Liu Y. Mpro-targeted anti-SARS-CoV-2 inhibitor-based drugs. J Chem Res. 2023;47(4):17475198231184799. https://doi.org/10.1177/17475198231184799
Alzyoud L, Ghattas MA, Atatreh N. Allosteric Binding Sites of the SARS-CoV-2 Main Protease: Potential Targets for Broad-Spectrum Anti-Coronavirus Agents. Drug Des Devel Ther. 2022;16:2463–78. https://doi.org/10.2147/DDDT.S370574
Hien TT Lai, Toan T Nguyen. Investigating structural features of dimeric SARS-CoV-2 Mpro catalytic site with bound covalent ligands at physiological temperature. J. Phys.: Conf. Ser. 2023;2485:012006. https://doi.org/10.1088/1742-6596/2485/1/012006
Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 2006;148(3):245–54. https://doi.org/10.1038/sj.bjp.0706736
Murdaca G, Paladin F, Tonacci A, Isola S, Allegra A, Gangemi S. The Potential Role of Cytokine Storm Pathway in the Clinical Course of Viral Respiratory Pandemic. Biomedicines. 2021;9(11):1688. https://doi.org/10.3390/biomedicines9111688
Zanza C, Romenskaya T, Manetti AC, Franceschi F, La Russa R, Bertozzi G, et al. Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. Medicina (Kaunas). 2022;58(2):144. https://doi.org/10.3390/medicina58020144
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminform. 2011;3:33. https://doi.org/10.1186/1758-2946-3-33
Søndergaard CR, Olsson MHM, Rostkowski M, Jensen JH. Improved treatment of ligands and coupling effects in empirical calculation and rationalization of pKa values. J Chem Theory Comput. 2011;7(7):2284–95. https://doi.org/10.1021/ct200133y
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–61. http://doi.org/10.1002/jcc.21334
Adasme MF, Linnemann KL, Bolz SN, Kaiser F, Salentin S, Haupt VH, et al. PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Res. 2021;49(W1):W530–34. http://doi.org/10.1093/nar/gkab294
Volkamer A, Griewel A, Grombacher T, Rarey M. Analyzing the topology of active sites: on the prediction of pockets and subpockets. J Chem Inf Model. 2010;50(11):2041–52. https://doi.org/10.1021/ci100241y
Schrödinger L, DeLano W. PyMOL [Internet]. [cited 2020]. Available from: http://www.pymol.org/pymol
Khmil NV, Kolesnikov VG. Molecular docking of human serum albumin with penicillin G’s determinants. Bіophysical bulletin. 2023;49:7–19. (In Ukrainian). https://doi.org/10.26565/2075-3810-2023-49-01
Ghosh R, Chakraborty A, Biswas A, Chowdhuri S. Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study. J Biomol Struct Dyn. 2022;40(5):2053–66. https://doi.org/10.1080/07391102.2020.1835728
RECOVERY Collaborative Group: Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693–704. https://doi.org/10.1056/NEJMoa2021436
Mishra A, Qais FA, Pathak Y, Camps I, Tripathi V. Triamcinolone as a Potential Inhibitor of SARS-CoV-2 Main Protease and Cytokine Storm: An In-silico Study. Lett Drug Des Discov. 2022;19(9). https://doi.org/10.2174/1570180819666220401142351
Tiwari G, Chauhan MS, Sharma D. Systematic In Silico Studies of Corticosteroids and Its Binding Affinities with Glucocorticoid Receptor for Covid-19 Treatment: Ab-Initio, Molecular Docking and MD Simulation Studies. Polycycl Aromat Comp. 2023;43(5):4654–69. https://doi.org/10.1080/10406638.2022.2092878
Fadaka AO, Sibuyi NRS, Madiehe AM, Meyer M. Computational insight of dexamethasone against potential targets of SARS-CoV-2. J Biomol Struct Dyn. 2022;40(2):875–85. https://doi.org/10.1080/07391102.2020.1819880
Weng YL, Naik SR, Dingelstad N, Lugo MR, Kalyaanamoorthy S, Ganesan A. Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity. Sci Rep. 2021;11:7429. https://doi.org/10.1038/s41598-021-86471-0
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
